Zihan Geng

Title: Zihan Geng: Innovator in Biopharmaceuticals

Introduction

Zihan Geng is a prominent inventor based in Beijing, China. He has made significant contributions to the field of biopharmaceuticals, particularly in the development of drug targets for the treatment of epithelial tumors. His innovative work has led to the filing of a patent that showcases his expertise and dedication to advancing medical science.

Latest Patents

Zihan Geng holds a patent titled "IgG epitope and applications thereof as a drug target." This patent describes the IgG epitope as the C1 domain of non-B cell-derived IgG, which features an N-glycosylated sialic acid modification at the Asn162 site. The functionality of this antigen is dependent on the sialylation of the site. The invention outlines the applications of the IgG epitope as a drug target for diagnosing and treating epithelial tumors. Furthermore, it highlights the role of sialyltransferase ST3GAL4 as a potential drug target for tumor therapeutic drugs. The research also indicates that integrin β4 is co-expressed and co-localized with IgG containing the epitope, suggesting that IgG can serve as a marker for auxiliary detection of epithelial tumors.

Career Highlights

Zihan Geng is associated with Beijing Sig Biopharmaceutical Technology Co., Ltd., where he continues to work on innovative solutions in the biopharmaceutical sector. His research and development efforts are focused on creating effective therapeutic strategies for cancer treatment.

Collaborations

Zihan collaborates with notable colleagues, including Xiaoyan Qiu and Jingshu Tang, who contribute to his research endeavors and help advance the goals of their projects.

Conclusion

Zihan Geng's contributions to the field of biopharmaceuticals through his innovative patent work exemplify his commitment to improving cancer treatment options. His research not only enhances our understanding of drug targets but also paves the way for future advancements in medical therapies.